SNSE Sensei Biotherapeutics, Inc.

Sensei is a clinical-stage immunotherapy company committed to the discovery and development of next-generation therapies for the treatment of cancer. Its proprietary ImmunoPhage? platform, leveraging the self-adjuvanted and highly immunogenic properties of engineered bacteriophage, allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach. Senseiís pipeline includes its lead product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck. Additional preclinical programs include SNS-401 for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.

$16.48  +0.19 (1.17%)
As of 02/26/2021 15:59:12 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA

02/04/2021
28,443,200
574,472
$469,312,800
0.00%
SEC Edgar Online
10-Q
10-K



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
4,386.10
0.00
-6,266.36%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy